Not medical advice. Talk to your provider before using any peptide. Full disclaimer
ACTH (Cosyntropin/Cortrosyn)
Also known as: ACTH, corticotropin, cosyntropin
Over 400 PubMed papers and six decades of clinical use make cosyntropin one of the most validated diagnostic tools in all of endocrinology. This synthetic 24-amino-acid fragment of ACTH triggers a measurable cortisol surge within 30 minutes, telling clinicians whether the adrenal glands can do their job. The full 39-amino-acid version, sold as HP Acthar Gel, carries FDA approval for infantile spasms, MS flares, and nephrotic syndrome. Cosyntropin isn't a research peptide or biohacking tool. It's a prescription diagnostic agent used in clinic settings, with a single standardized dose (250 mcg) that hasn't changed in decades.
What Is ACTH (Cosyntropin/Cortrosyn)?
Four hundred twenty-four PubMed-indexed papers, a 2023 patient-level meta-analysis (Kazlauskaite et al., PMC10045406), and decades of routine hospital use. That's the evidence base behind the cosyntropin stimulation test. Adrenocorticotropic hormone (ACTH, also known as corticotropin; CAS 9002-60-2) is a 39-amino-acid peptide produced by corticotroph cells in the anterior pituitary gland. Cosyntropin (brand name Cortrosyn) is the synthetic 24-amino-acid N-terminal fragment. It retains full biological activity at the melanocortin-2 receptor (MC2R) on adrenal cortical cells.
The test itself is simple. A clinician injects 250 mcg intravenously or intramuscularly, draws cortisol at baseline, 30 minutes, and 60 minutes. Peak cortisol at or above 18 mcg/dL means the adrenals are functioning. Anything below that threshold raises a red flag for Addison's disease or secondary adrenal insufficiency.
Beyond diagnostics, the full-length ACTH molecule appears in HP Acthar Gel, a repository corticotropin preparation derived from porcine pituitary extract. Acthar carries FDA approval for infantile spasms (first-line per AAP guidelines), MS exacerbations, nephrotic syndrome, and more than a dozen other inflammatory conditions. Its price tag, roughly $45,600 per vial, makes it one of the most expensive drugs in the United States.
Reddit mentions for cosyntropin sit near zero. There is no community peptide protocol. This is a clinical compound prescribed by endocrinologists, neurologists, and nephrologists. The plasma half-life is approximately 15 minutes, meaning it clears the body before the diagnostic blood draw at 60 minutes is even complete.
How ACTH (Cosyntropin/Cortrosyn) Works
ACTH binds to the melanocortin-2 receptor (MC2R), a G protein-coupled receptor found primarily on cells in the adrenal cortex zona fasciculata and zona reticularis. MC2R is unusual among melanocortin receptors because ACTH is its only known endogenous agonist. The receptor also requires a chaperone protein called MRAP1 (melanocortin-2 receptor accessory protein) to reach the cell surface. Without MRAP1, MC2R gets trapped in the endoplasmic reticulum and degraded.
Once ACTH locks onto MC2R, the receptor activates the stimulatory G-protein (Gs). Gs turns on adenylyl cyclase, which converts ATP into cyclic AMP. Rising cAMP levels activate protein kinase A (PKA). PKA then phosphorylates two key enzymes in the steroidogenic pathway: StAR protein and CYP11A1 (cytochrome P450 side-chain cleavage enzyme). Together, these drive the rate-limiting conversion of cholesterol into pregnenolone. The downstream result is cortisol, corticosterone, and adrenal androgen production.
ACTH-related melanocortin peptides also activate MC1R, MC3R, MC4R, and MC5R on immune cells (macrophages, lymphocytes, dendritic cells). This explains why Acthar Gel produces anti-inflammatory effects independent of cortisol. Those non-steroidogenic effects include suppression of NF-kB signaling and reduced pro-inflammatory cytokine release.
ACTH (Cosyntropin/Cortrosyn) Benefits
- ACTH benefits center on its dual role as a diagnostic gold standard and a therapeutic option for severe inflammatory conditions.
- Cosyntropin has been the international standard for diagnosing adrenal insufficiency for over 50 years, used in virtually every endocrinology practice worldwide.
- Acthar Gel achieves approximately 87% response rates for infantile spasms in published series, earning first-line recommendation from the American Academy of Pediatrics and Child Neurology Society.
- MS exacerbation treatment with Acthar Gel (80-120 U/day for 2-3 weeks) provides an alternative for patients who cannot tolerate IV methylprednisolone.
- Direct immunomodulatory effects through melanocortin receptors on immune cells offer a mechanism distinct from simple cortisol elevation, suppressing NF-kB signaling and B-cell antibody production [1].
- The 2023 meta-analysis by Kazlauskaite's group (PMC10045406) confirmed that even the low-dose 1 mcg protocol detects secondary adrenal insufficiency with higher sensitivity than the standard 250 mcg dose.
ACTH (Cosyntropin/Cortrosyn): Science vs Community Consensus
Cosyntropin is one of the most validated diagnostic tools in endocrinology, with over 400 PubMed-indexed papers spanning decades.
Read the evidence (key study, limitations)
The 250 mcg stimulation test is the international standard for evaluating adrenal reserve. A 2023 patient-level meta-analysis found the low-dose test (1 mcg) has better sensitivity for detecting secondary adrenal insufficiency than the standard 250 mcg dose, but the standard dose remains the clinical default due to simplicity and reproducibility. Acthar Gel therapeutic efficacy is well-documented for infantile spasms (first-line per AAP guidelines), MS exacerbations, and nephrotic syndrome, but its advantages over cheaper corticosteroid alternatives are debated.
Kazlauskaite et al. 2023, "ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow" (PMC10045406): patient-level meta-analysis showing low-dose test superiority for secondary AI detection
The standard 250 mcg dose provides supraphysiologic stimulation that may mask mild or early secondary adrenal insufficiency: a known limitation. The low-dose (1 mcg) protocol isn't FDA-approved and requires dilution of the 250 mcg vial, introducing preparation variability. Acthar Gel's superiority over IV methylprednisolone for MS is not established: the high price tag makes the cost-benefit analysis unfavorable for many indications.
There is effectively no community use of cosyntropin as a research peptide.
Read the reports (what users report 3, common issues 5)
Reddit mentions are near zero. This is a clinical diagnostic agent administered by doctors in clinic settings: it has no application in the peptide optimization community. Acthar Gel patient communities exist (primarily for infantile spasms and MS), but discussion centers on cost, insurance battles, and side effects, not self-directed protocols.
- Acthar Gel for infantile spasms: parents describe it as life-changing when other treatments fail
- MS exacerbation relief: some patients prefer it to IV steroids for relapse management
- Acthar Gel SelfJect auto-injector makes home administration easier than older vial-and-syringe method
- Cost is the overwhelming complaint: ~$45,600 per vial makes it one of the most expensive drugs in the US
- Insurance denials and prior authorization battles are routine
- Cushingoid side effects with chronic use: weight gain, moon face, fluid retention
- Hyperglycemia requiring monitoring or treatment adjustment
- Mood changes and insomnia during therapeutic courses
Scientific data is extensive for cosyntropin as a diagnostic tool and Acthar Gel as a therapeutic agent. There is no community peptide use to align with: this is a clinical-only compound. The "community" that exists (Acthar Gel patients) interacts with this drug exclusively through physician prescriptions, not self-directed protocols.
ACTH (Cosyntropin/Cortrosyn) Dosage Guide
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 250 mcg | Single dose |
| Moderate | 250 mcg | Single dose |
| Aggressive | 250 mcg | Single dose |
Cosyntropin comes in a 0.25 mg vial. Reconstitute with 1 mL of normal saline (0.9% NaCl), not bacteriostatic water. The manufacturer is specific about this. You'll draw up the entire 1 mL for the full 250 mcg diagnostic dose. There's no partial dosing for adults.
The timing matters more than most people realize. Morning testing (8-9 AM) is preferred because cortisol follows a diurnal rhythm; afternoon testing can produce misleading baseline values. Draw your baseline cortisol before touching the cosyntropin. Then collect at both 30 and 60 minutes. Some patients with intact adrenal function peak late, and calling it a failure based on one timepoint is a common diagnostic error.
Stop glucocorticoids on the day of testing. Estrogen-containing drugs need a 4-6 week washout because they raise cortisol-binding globulin. Miss that detail and you'll get a falsely raised total cortisol reading.
Use reconstituted cosyntropin immediately. Don't store it. Don't batch it. One vial, one test, one patient.
Cycling
Neither form of ACTH is cycled. Cosyntropin (Cortrosyn) is one 0.25 mg injection in adults to screen for adrenocortical insufficiency, not a course (Cortrosyn label, sections 1, 2.2 and 16). Acthar Gel runs as a course or a per-patient schedule, never an on/off cycle. For infantile spasms, the Acthar Gel label gives 150 U/m2 a day over a 2-week period (section 2.2). Dosing is then "gradually tapered over a 2-week period to avoid adrenal insufficiency." Acute multiple sclerosis exacerbations get 80 to 120 units daily for 2-3 weeks (section 2.3). Stopping suddenly after prolonged use "may lead to adrenal insufficiency or recurrent symptoms" (sections 2.3 and 2.4). It may be necessary to taper the dose and lengthen the injection interval (sections 2.3, 2.4 and 5.2).
Cosyntropin is a single diagnostic dose: cycling doesn't apply. For therapeutic Acthar Gel, the labelled courses are time-limited: 80 to 120 units daily for 2-3 weeks for MS exacerbations (section 2.3), and 2 weeks of dosing plus a 2-week taper "to avoid adrenal insufficiency" for infantile spasms (section 2.2). Neither label sets an on/off cycle or an off period. Other conditions are dosed per patient, usually 40 to 80 units every 24 to 72 hours (Acthar Gel label, section 2.4).
- Cushingoid features developing (moon face, central weight gain, striae): indicates excessive cortisol exposure
- Hyperglycemia or new-onset diabetes: ACTH-driven cortisol is raising blood sugar beyond safe levels
- Low morning cortisol after stopping treatment: HPA axis hasn't recovered; may need hydrocortisone bridging
- Recurrent infections: immunosuppression from sustained cortisol elevation
Or use the universal Peptide Calculator for any peptide.
ACTH (Cosyntropin/Cortrosyn) Protocols by Goal
Expected: Definitive assessment of adrenal reserve. Normal response: cortisol rises to ≥18-20 mcg/dL. Subnormal response indicates adrenocortical insufficiency requiring further workup (ACTH level to distinguish primary vs secondary AI).
Monitor: Cortisol assay at baseline, 30 min, 60 min. Some guidelines recommend measuring both timepoints: patients failing at 30 min may pass at 60 min.
How to Inject ACTH (Cosyntropin/Cortrosyn)
- 1Step 1
Remove the flip-off seal from the cosyntropin 0.25 mg vial.
- 2Step 2
Using a sterile syringe, inject 1 mL of 0.9% sodium chloride (normal saline) into the vial. Swirl gently until dissolved. The solution should be clear and colorless.
- 3Step 3
Draw baseline serum cortisol before proceeding.
- 4Draw up the full 1 mL (250 mcg) into the syringe
For IV administration, push slowly over 2 minutes. For IM, inject into the deltoid or gluteal muscle using a 22-25 gauge needle.
- 5Step 5
Start a timer at the moment of injection.
- 6Step 6
Draw serum cortisol at 30 minutes post-injection and again at 60 minutes. Label tubes clearly with draw times.
- 7Step 7
Normal result: peak cortisol at or above 18-20 mcg/dL at either timepoint.
- 8Step 8
For Acthar Gel (therapeutic use): administer IM or subcutaneously. Infantile spasms protocol calls for 150 U/m2/day divided into two injections. MS exacerbation dosing runs 80-120 units once daily for 2-3 weeks. Rotate injection sites for repeated dosing.
- 9Step 9
Storage: cosyntropin vials store at room temperature (15-30 degrees C). Protect from light. Acthar Gel requires cold chain storage per Mallinckrodt labeling.
ACTH (Cosyntropin/Cortrosyn) Stacking Protocols
Works With
Avoid
Falsely elevate cortisol during diagnostic testing. For therapeutic Acthar Gel, concurrent glucocorticoids create additive immunosuppression and Cushingoid risk.
Do not combineIncrease cortisol-binding globulin, falsely elevating total cortisol measurements. Stop 4-6 weeks before cosyntropin testing.
Can interfere with cortisol assay results during stimulation testing.
Contraindicated during therapeutic Acthar Gel use due to immunosuppressive effects: risk of disseminated infection.
Do not combineEnhanced risk of severe hypokalemia when combined with corticotropin therapy.
Do not combineEstimated Cost
Pricing updated 2026-04-09
ACTH (Cosyntropin/Cortrosyn) Side Effects
Acthar Gel's chronic side effect profile looks a lot like what happens when you flood the body with cortisol, because that's exactly what it does. Cushingoid features (moon face, central weight gain, abdominal striae) develop in most patients by week two of daily dosing. This isn't a rare side effect. It's an expected pharmacologic consequence of sustained ACTH stimulation.
Hyperglycemia is the second concern that warrants real attention. ACTH-driven cortisol elevation raises blood glucose enough to unmask diabetes in predisposed patients. Blood glucose monitoring during any Acthar Gel course longer than a few days isn't optional.
Hypokalemia represents a less obvious but potentially dangerous risk. Mineralocorticoid effects from adrenal stimulation cause potassium wasting. The risk compounds when patients are also taking amphotericin B or loop diuretics. Weekly serum potassium checks are standard during therapeutic courses.
For the single diagnostic dose of cosyntropin (250 mcg), adverse effects are far less dramatic. Hypersensitivity reactions occur infrequently. Anaphylaxis is rare but documented even on first exposure, which is why every cosyntropin stimulation test requires epinephrine on hand and IV access established before the injection.
Published side effects from the single diagnostic dose include bradycardia, tachycardia, transient hypertension, peripheral edema, and injection-site rash. These are uncommon and typically self-limited.
Chronic Acthar Gel use carries additional risks: fluid retention, increased infection susceptibility, osteoporosis with prolonged courses, cataracts, peptic ulceration, mood disturbances (ranging from insomnia to frank psychosis), and skin hyperpigmentation from melanocortin receptor activation. Neutralizing antibody formation has been reported with prolonged administration.
Abrupt discontinuation after courses longer than one week can precipitate adrenal crisis. This is not a theoretical risk. HPA axis suppression from exogenous ACTH is predictable and dose-dependent. Tapering protocols are mandatory. If morning cortisol falls below 10 mcg/dL after completing a course, hydrocortisone bridging may be necessary until the axis recovers.
Pregnancy is not on either repository corticotropin label's contraindication list. The Acthar Gel label says it may cause fetal harm (section 8.1), and the Cortrophin label cites fetal abnormalities in animals, so use it only if the benefit justifies the risk. Breastfeeding requires caution since ACTH-stimulated cortisol elevation may affect nursing infants.
Common Issues & Solutions
Cortisol didn't reach 18 mcg/dL at 30 minutes? Always check the 60-minute draw: some patients with intact adrenal function have a delayed peak. Over-diagnosing adrenal insufficiency from a single timepoint is a common pitfall.
Used bacteriostatic water instead of normal saline? The manufacturer specifies 0.9% NaCl only. BAC water may affect stability. Re-do the test with proper reconstitution.
Patient on glucocorticoids? Prednisone, hydrocortisone, and dexamethasone must be discontinued on the day of testing. Estrogens need 4-6 weeks washout. A "failed" test on these drugs is a false result, not adrenal insufficiency.
Anaphylactic reaction during test? It's rare but documented even on first exposure. Always have epinephrine, IV access, and resuscitation equipment ready. Don't perform this test without emergency preparedness.
Acthar Gel too expensive to access? At ~$45,600 per vial, this is one of the most controversial drug prices in the US. Mallinckrodt offers patient assistance programs (Acthar Patient Support). Discuss alternatives with your prescriber: IV methylprednisolone covers many of the same indications at a fraction of the cost.
Ask AI about this page
Ask AI for a second opinion on ACTH (Cosyntropin/Cortrosyn) dosing and side effects
Contraindications
- Primary adrenocortical insufficiency (adrenals cannot respond to ACTH stimulation)
- Intravenous administration of repository corticotropin: contraindicated on the Acthar Gel and Purified Cortrophin Gel labels
- Infants under 2 years of age with suspected congenital infections (Acthar Gel label)
- Live or live attenuated vaccines during immunosuppressive doses of repository corticotropin (Acthar Gel label)
- Systemic fungal infections or active untreated infections
- Ocular herpes simplex: contraindicated on both repository corticotropin labels
- Recent surgery: contraindicated on both repository corticotropin labels
- Scleroderma (manufacturer contraindication for corticotropin therapy)
- Peptic ulcer, active or by history: contraindicated on both repository corticotropin labels
- Osteoporosis: contraindicated on both repository corticotropin labels
- Congestive heart failure or uncontrolled hypertension (for therapeutic corticotropin)
- Adrenocortical hyperfunction: contraindicated on both repository corticotropin labels
- Sensitivity to proteins of porcine origin: contraindicated on both repository corticotropin labels
- Hypersensitivity to cosyntropin or any component of the formulation
- Prior hypersensitivity to corticotropin or any inactive ingredient: contraindicated on the Acthar Gel and Purified Cortrophin Gel labels since October 2026; reactions have included anaphylaxis and angioedema
- Pregnancy: not a label contraindication, but the Acthar Gel label says it may cause fetal harm (section 8.1); use only if potential benefit justifies risk
- Breastfeeding: ACTH-stimulated cortisol elevation may affect nursing infants; use with caution
Drug Interactions
- Glucocorticoids and spironolactone: Falsely elevate cortisol levels during diagnostic testing; discontinue on day of test
- Estrogen-containing drugs: Increase cortisol binding globulin levels; stop 4-6 weeks before cosyntropin testing
- Amphotericin B: Enhanced risk of severe hypokalemia when combined with corticotropin therapy
- Quinolone antibiotics: Increased risk of tendon rupture when co-administered with corticotropin
- Live vaccines: Contraindicated during therapeutic corticotropin use due to immunosuppressive effects
- NSAIDs (ibuprofen, naproxen, aspirin): increased GI bleeding risk from combined corticotropin-induced mucosal vulnerability; per Acthar Gel prescribing information
- Oral anticoagulants (warfarin): corticotropin-driven cortisol elevation may alter coagulation factor synthesis; monitor INR when initiating or discontinuing corticotropin; per Acthar Gel prescribing information
- Insulin and oral hypoglycemic agents: ACTH-driven adrenal cortisol elevation causes hyperglycemia; patients with diabetes may require dose adjustments during corticotropin therapy; per clinical pharmacology
Product Quality
Cosyntropin (Cortrosyn) is a fully FDA-approved pharmaceutical product manufactured under GMP conditions by Amphastar Pharmaceuticals. Acthar Gel is manufactured by Mallinckrodt. Neither product typically comes from compounding pharmacies or the research-chemical market. Counterfeiting risk is negligible because these are hospital/clinic supply items dispensed through regulated pharmaceutical channels.
- Cosyntropin is a prescription product: it should come from a licensed pharmacy or hospital supply, never the research-peptide market
- Reconstitute with normal saline only: the manufacturer specifies 0.9% NaCl, not bacteriostatic water
- Check expiration dates: cosyntropin is stable at room temperature but use reconstituted solution immediately
- Acthar Gel should always come with the Mallinckrodt label and proper cold chain documentation
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Serum cortisol (baseline, 30 min, 60 min) | During cosyntropin stimulation test | ≥18-20 mcg/dL peak |
| Blood glucose | During and after Acthar Gel therapeutic courses | Fasting <126 mg/dL |
| Serum potassium | Weekly during Acthar Gel therapy | 3.5-5.0 mEq/L |
| Blood pressure | Each visit during Acthar Gel therapy | <140/90 mmHg |
| Morning cortisol (post-treatment) | After completing an Acthar Gel course >1 week | ≥10 mcg/dL (AM draw) |
The entire point of the diagnostic test: determines adrenal reserve adequacy
Chronic ACTH stimulation elevates cortisol, which raises blood glucose. Can unmask diabetes.
Mineralocorticoid effects cause potassium wasting: hypokalemia risk increases with concurrent amphotericin B or diuretics
Fluid retention and mineralocorticoid effects raise blood pressure
Assesses HPA axis recovery after exogenous ACTH suppression. Low morning cortisol indicates ongoing adrenal suppression requiring continued physiologic replacement.
ACTH (Cosyntropin/Cortrosyn) Before and After
Diagnostic: Cortisol begins rising within minutes of cosyntropin injection. Initial adrenal response measurable by 30 minutes post-dose.
Diagnostic: Peak cortisol response typically reached at 30-60 minutes. Normal response is cortisol ≥18-20 mcg/dL confirming adequate adrenal reserve.
Therapeutic (Acthar Gel): Clinical improvement in infantile spasms and MS exacerbations typically observed within the first 1-2 weeks of daily dosing.
Therapeutic: Full treatment effect realized. Begin tapering protocols to prevent adrenal suppression and rebound symptoms.
What to Expect
0-30 minutes (Diagnostic): Cortisol starts climbing within minutes of the cosyntropin injection. By 30 minutes, the adrenal response is measurable. This first blood draw gives an early read on whether the glands are responding. Cosyntropin's 15-minute half-life means it's already clearing the bloodstream at this point.
30-60 minutes (Diagnostic): Peak cortisol typically lands in this window. Anything at or above 18-20 mcg/dL confirms the adrenals have adequate reserve. Patients report the test itself as straightforward and painless. By 60 minutes, the cosyntropin has cleared plasma entirely.
1-2 weeks (Acthar Gel Therapeutic): Clinical improvement typically appears within the first two weeks of daily dosing. Parents of infants with West syndrome report dramatic spasm reduction early in this window. MS patients have more variable onset; some feel relief within days while others need the full course. Expect fluid retention, mood changes, increased appetite, insomnia, and raised blood glucose during this phase.
2-4 weeks (Acthar Gel Therapeutic): Full treatment effect is realized. Mandatory taper begins to prevent adrenal crisis and rebound. Cushingoid features have appeared in most patients by now (moon face, weight gain). Parents and MS patients describe the taper phase as challenging since symptoms can fluctuate. Hyperglycemia, hypokalemia, infection risk, and mood swings are common during this period.
Detailed Timeline: Science vs Community
Cortisol begins rising within minutes of cosyntropin injection. Measurable cortisol increase at 30 minutes. Target: ≥18 mcg/dL.
N/A: not community-used. Patients report the test itself is straightforward and painless.
Peak cortisol typically reached. Normal response ≥18-20 mcg/dL confirms adequate adrenal reserve. Cosyntropin has cleared plasma by this point (t½ ~15 min).
N/A: the test is over. Results interpreted by the ordering physician.
Infantile spasms: cessation or significant reduction expected within 2 weeks. MS exacerbations: symptom improvement beginning within days to 1 week.
Parents of infants with West syndrome report dramatic spasm reduction in the first 1-2 weeks. MS patients report variable onset: some improve within days, others take the full course.
Full treatment effect realized. Begin mandatory taper to prevent adrenal crisis and rebound.
Cushingoid features appear in most patients by this point (moon face, weight gain). Parents and MS patients report the taper phase as challenging: symptoms can fluctuate.
Pharmacokinetics
Source: FDA label and clinical pharmacology references; cosyntropin plasma half-life ~15 minutes
Pharmacokinetics: Active Dose Over Time
t½ = ~15 minutesDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is ACTH (Cosyntropin/Cortrosyn) Legal?
Cosyntropin (Cortrosyn) holds full FDA approval as a diagnostic agent for screening adrenocortical insufficiency. It is manufactured by Amphastar Pharmaceuticals under GMP conditions and dispensed through regulated pharmaceutical channels. Generic cosyntropin is available at comparable pricing.
HP Acthar Gel (repository corticotropin injection) is separately FDA-approved by Mallinckrodt Pharmaceuticals for over a dozen indications including infantile spasms, MS exacerbations, and nephrotic syndrome. It holds grandfathered FDA status with no generic equivalent due to its unique porcine-derived formulation. Purified Cortrophin Gel (repository corticotropin injection, ANI Pharmaceuticals, NDA 008975) is the other repository corticotropin product on the US market, and FDA cleared its matching hypersensitivity contraindication on October 5, 2026.
ACTH is explicitly listed on the WADA Prohibited List under S2.2.2 (Corticotrophins and Their Releasing Factors). It is banned both in-competition and out-of-competition. This covers cosyntropin, tetracosactide, and repository corticotropin. Documented doping cases exist in professional cycling.
Neither cosyntropin nor Acthar Gel is available from compounding pharmacies or as a research peptide. These are manufactured pharmaceutical products requiring a prescription. This content is for informational purposes only and does not constitute medical advice.
Who Should Consider ACTH (Cosyntropin/Cortrosyn)
- Patients undergoing evaluation for adrenal insufficiency
- Infants with infantile spasms (West syndrome)
- Multiple sclerosis patients experiencing acute exacerbations
- Nephrotic syndrome patients refractory to conventional therapy
- Rheumatology patients with acute flares of inflammatory conditions
Related Peptides
What Changed for ACTH (Cosyntropin/Cortrosyn)
- Safety
Corrected Oct 18, 2026: pregnancy is a label warning for repository corticotropin, not a contraindication; Acthar Gel may cause fetal harm, per the label.
Before: Pregnancy is contraindicated for therapeutic corticotropin. Animal studies showed embryocidal effects. After: Pregnancy is not on either repository corticotropin label's contraindication list; Acthar Gel may cause fetal harm (section 8.1), so use it only if the benefit justifies the risk
What this does not mean: Pregnancy still carries the warning (section 8.1). The page had said pregnancy is contraindicated for therapeutic corticotropin; neither the Acthar Gel nor the Cortrophin Gel contraindication list names it.
Source: Acthar Gel (repository corticotropin injection) prescribing information, NDA 008372 supplement 088, revised 10/2026 (Drugs@FDA label; Recent Major Changes: Contraindications (4) and Warnings and Precautions (5.10), 10/2026) (opens in a new tab) · Saved copy
- Safety
Corrected Oct 18, 2026: pregnancy is a label warning for Acthar Gel, not a contraindication, per the label, sections 4 and 8.1.
Before: Pregnancy: corticotropin has embryocidal effects in animal studies; use only if potential benefit justifies risk After: Pregnancy: not a label contraindication, but the Acthar Gel label says it may cause fetal harm (section 8.1); use only if potential benefit justifies risk
What this does not mean: Acthar Gel may cause fetal harm, so pregnancy stays on the list as a warning. The page had cited embryocidal effects in animals; the label says its developmental effects were not adequately assessed in animals.
Source: Acthar Gel (repository corticotropin injection) prescribing information, NDA 008372 supplement 088, revised 10/2026 (Drugs@FDA label; Recent Major Changes: Contraindications (4) and Warnings and Precautions (5.10), 10/2026) (opens in a new tab) · Saved copy
- Safety
Corrected Oct 17, 2026: ACTH now carries the Acthar Gel section 4 contraindications, including intravenous use, live vaccines and peptic ulcer, per the label.
Before: Peptic ulcer and osteoporosis as cautions; no intravenous, infants under 2, live vaccine, ocular herpes simplex, recent surgery, adrenocortical hyperfunction or porcine protein item After: The label section 4 list: intravenous use, infants under 2 with suspected congenital infections, live vaccines, scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction and porcine protein sensitivity
What this does not mean: Doses and indications did not change. Cortrophin Gel lists all but the infant and live-vaccine lines. The page had called peptic ulcer and osteoporosis cautions and omitted intravenous use, live vaccines and recent surgery.
Source: Acthar Gel (repository corticotropin injection) prescribing information, NDA 008372 supplement 088, revised 10/2026 (Drugs@FDA label; Recent Major Changes: Contraindications (4) and Warnings and Precautions (5.10), 10/2026) (opens in a new tab) · Saved copy
- Safety
FDA made a past hypersensitivity reaction to corticotropin a contraindication for Acthar Gel on Oct 5, 2026, citing anaphylaxis and angioedema, per the label.
Before: No corticotropin hypersensitivity line; the only hypersensitivity item named cosyntropin. After: Prior hypersensitivity to corticotropin or any inactive ingredient: contraindicated on the Acthar Gel and Purified Cortrophin Gel labels since October 2026; reactions have included anaphylaxis and angioedema
What this does not mean: Doses and indications did not change. It is one FDA-required change for ACTH products: Purified Cortrophin Gel gained the same contraindication the same day. No cosyntropin (Cortrosyn) label changed.
Source: Acthar Gel (repository corticotropin injection) prescribing information, NDA 008372 supplement 088, revised 10/2026 (Drugs@FDA label; Recent Major Changes: Contraindications (4) and Warnings and Precautions (5.10), 10/2026) (opens in a new tab) · Saved copy
Peptide Schedule Research TeamReviewed Apr 8, 20265 Citations
References
- [1]Acthar Gel Treatment for Patients with Autoimmune and Inflammatory Diseases (opens in a new tab)PubMed (opens in a new tab)Review
Additional References
- Cosyntropin as a diagnostic agent in the screening of patients for adrenocortical insufficiency (opens in a new tab)PubMed 22291489Review
- ACTH receptor (MC2R) specificity: what do we know about underlying molecular mechanisms? (opens in a new tab)PubMed 28220105Review
- Cortrosyn (cosyntropin) FDA Prescribing Information (opens in a new tab)FDA Label
- PMC10045406 (PMC10045406) (opens in a new tab)PubMed
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is ACTH (Cosyntropin/Cortrosyn)?
Niche. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 0. Community mentions on Reddit: ~0 (effectively zero research peptide discussion).
424 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.